DRAWING SHEET 1/25




FIGURE 1

DRAWING SHEET 2/25




FIGURE 2

DRAWING SHEET 3/25




FIGURE 3

DRAWING SHEET 4/25




FIGURE 4

DRAWING SHEET 5/25




FIGURE 5

DRAWING SHEET 6/25




FIGURE 6

DRAWING SHEET 7/25




FIGURE 7

DRAWING SHEET 8/25




FIGURE 8

DRAWING SHEET 9/25

Activated MK2 Differentially Expressed in Human IPF vs. Normal Lung




FIGURE 9

DRAWING SHEET 10/25

Bleomycin Model of Idiopathic Pulmonary Fibrosis: Prevention Model




FIGURE 10

DRAWING SHEET 11/25

MMI-0100 Inhibits Development of Fibrosis in Idiopathic Pulmonary Fibrosis Prevention Model




FIGURE 11

DRAWING SHEET 12/25




FIGURE 12

DRAWING SHEET 13/25

MMI-0100 Dose-Response Data in Idiopathic Pulmonary Fibrosis Prevention Model




FIGURE 13

DRAWING SHEET 14/25




FIGURE 14

DRAWING SHEET 15/25




FIGURE 15

DRAWING SHEET 16/25

MMI-0100 Ameliorates Fibrosis in IPF Treatment Model




FIGURE 16

DRAWING SHEET 17/25





FIGURE 17

DRAWING SHEET 18/25

Reduced Activated MK2 with MMI-0100 in IPF Treatment Model



50 µg/kg 50 µg/kg

FIGURE 18

DRAWING SHEET 19/25




FIGURE 19

DRAWING SHEET 20/25




FIGURE 20

DRAWING SHEET 21/25

MMI-0100 Inhibits Myofibroblast (a-SMA) Activation in IPF Treatment Model




FIGURE 21

DRAWING SHEET 22/25




FIGURE 22

DRAWING SHEET 23/25




FIGURE 23

DRAWING SHEET 24/25

MSC migration is regulated by fibronectin through α5β1-integrin-mediated activation of PDGFR-β





FIGURE 24

DRAWING SHEET 25/25

A



B




FIGURE 25